A rapid screening tool for fatigue impact in multiple sclerosis by Kos, Daphne et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Neurology
Open Access Research article
A rapid screening tool for fatigue impact in multiple sclerosis
Daphne Kos*1,3, Guy Nagels2, Marie B D'Hooghe2, Marijke Duportail3 and 
Eric Kerckhofs1
Address: 1Department of Rehabilitation Research, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium, 2Department of Neurology, 
National MS Centre Melsbroek, Belgium and 3Department of Occupational Therapy, National MS Centre Melsbroek, Belgium
Email: Daphne Kos* - Daphne.Kos@vub.ac.be; Guy Nagels - guy.nagels@ms-centrum.be; Marie B D'Hooghe - marie.dhooghe@ms-centrum.be; 
Marijke Duportail - marijke.duportail@ms-centrum.be; Eric Kerckhofs - ekerckh@vub.ac.be
* Corresponding author    
Abstract
Background: Fatigue is a common complaint in multiple sclerosis (MS) and often interferes with
daily functioning. Both clinicians and researchers may need to detect high levels of fatigue impact
using a time and effort efficient tool. This study evaluates the psychometric properties of a rapid
screening instrument for fatigue impact in multiple sclerosis.
Methods: Three visual analogue scales (VAS) for assessing the impact of fatigue were developed.
Sixty two subjects with definite MS (mean age 52 +/- 10.5 years; 29 women) and 24 healthy controls
(mean age 52 +/- 14 years; 13 women) completed all VAS scales (range 0–100), the Fatigue Severity
Scale (FSS) (range 7–63), the Modified Fatigue Impact Scale (MFIS) (range 0–84) and the Guy's
Neurological Disability Scale (GNDS) (range 0–5). All tests were repeated with an interval of
maximum three days.
To evaluate the reproducibility, intraclass correlations (ICC) were calculated, based on one-way
analysis of variance for repeated measurements. Validity was considered by means of correlation
coefficients. ROC analysis was used to determine the accuracy of the VAS scales.
Results: The ICC of the VAS scales ranged from 0.68 to 0.69. VAS scales showed low to moderate
correlation with FSS, MFIS and GNDS (Kendall's tau 0.23–0.45) and were not related with physical
or cognitive performance, or with depression. All VAS scales were able to discriminate between
subjects with MS and controls. Twenty five subjects with MS had a Fatigue Severity Scale score of
36 or more and were classified into the "fatigue" group. ROC analysis showed that VAS_1 is most
useful to classify subjects in the "fatigue" group. A cut-off value of VAS_1 of 59 displayed 76%
sensitivity and 72% specificity. When using the MFIS score of 40 or more to classify the groups,
VAS_1 remained the strongest tool, with 81% sensitivity and 77% specificity at a cut-off value of 59.
Conclusion: The VAS for the impact of fatigue on daily life (VAS_1) is a moderately reliable,
though valid and useful tool to screen rapidly for fatigue impact in multiple sclerosis. A cut-off value
of 59 satisfactorily classifies individuals having severe fatigue with a high impact on daily life. In
clinical practice, a more comprehensive assessment of fatigue and the impact on daily life is
recommended.
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Background
In multiple sclerosis, fatigue limits the daily life function-
ing to a great extent [1]. For example, fatigue is one of the
major reasons for unemployment in multiple sclerosis
[2].
The influence of fatigue on performance is commonly
quantified by self-report instruments. Several instruments
have been developed and evaluated, though no "golden
standard" exists. The choice of an instrument mainly
depends on the purpose, e.g. Fatigue Severity Scale (FSS)
is used to assess the severity of fatigue [3]. Having severe
fatigue does not necessarily mean a high degree of limita-
tion in his or her daily life. Inversely, some people with
less severe fatigue feel they are enormously limited in their
activities. Therefore it is important to search for the most
appropriate tool for a particular dimension of fatigue.
In intervention studies evaluating strategies to reduce
fatigue (medication, cooling, energy management etc.),
one of the inclusion criteria is usually a certain degree of
fatigue (impact). The most commonly used instruments
for this purpose are the Fatigue Severity Scale or the (Mod-
ified) Fatigue Impact Scale. However, the administration
of these scales takes some time (10–20 minutes) and they
are often used as outcome measures as well.
Visual analogue scales (VAS) are frequently used to assess
subjective feelings, like pain and fatigue. However, reports
of research evaluating the scientific properties of the scales
are sparse [4,5]. Besides, nearly every VAS is unique when
different expressions are used.
We developed three potential visual analogue scales to
rapidly assess the impact of fatigue in multiple sclerosis.
This study evaluates the reproducibility and the validity of
the scales and determines the most appropriate VAS for
screening purposes.
Methods
Sample
The study ethics committee of the National MS Centre of
Melsbroek approved the study, and informed consent was
obtained from all participants.
Out of all in- and outpatients attending the rehabilitation
service of the National MS Centre of Melsbroek (Bel-
gium), an electronic randomization assigned 85 individu-
als with clinically definite MS to the study group. Subjects
were included when adequate physical (upper limb) and
cognitive functioning was demonstrated. The physical
performance was determined by a minimum score of 30
or more on the self-care subscore of the Functional Inde-
pendence Measure; adequate cognitive functioning was
demonstrated by a Rao's neuro-psychological battery [6]
of 3 or more. Sixty two individuals met all criteria and
were included in the study. Twenty four employees of the
centre volunteered as healthy controls, one of them did
not perform the second assessment.
Procedure
Three Visual Analogue Scales to assess the impact of
fatigue on daily life (VAS_1), on self care activities
(VAS_2) and on household and occupation (VAS_3) were
developed. The answer line of 100 mm ranges from "no
influence at all" to "a lot of influence" (Figure 1).
Visual Analogue Scales for the impact of fatigue Figure 1
Visual Analogue Scales for the impact of fatigue.BMC Neurology 2006, 6:27 http://www.biomedcentral.com/1471-2377/6/27
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The three VAS scales were administered simultaneously
with the Modified Fatigue Impact Scale (MFIS), the
Fatigue Severity Scale (FSS) and the fatigue subscale of the
Guy's Neurological Disability Scale (GNDS), in a random
order.
The Modified Fatigue Impact Scale assesses the impact of
fatigue on daily functioning during the last four weeks.
Subjects are requested to indicate the frequency of influ-
ence of fatigue in 21 situations (range 0–4), resulting in a
total score and three subscores (physical, cognitive and
psychosocial subscale) [7-9].
In the Fatigue Severity Scale (FSS), individuals have to rate
their agreement (range 1–7) with nine statements con-
cerning the severity, frequency and impact of fatigue on
daily life [10].
The Guy's Neurological Disability Scale (GNDS) is a disa-
bility measure developed for use in multiple sclerosis; it
consists of 12 categories, including fatigue. The fatigue
score (range 0–5) is based on the presence and severity of
fatigue and its impact during the last four weeks [11,12].
Divergent validity was considered with Kurtzke's
Expanded Disability Status Scale [13], the Functional
Independence Measure [14], the neuro-psychological bat-
tery of Rao [6,15] and Zung self-rating depression scale
[16].
To evaluate the reproducibility of the scale, the measure-
ment was repeated within three days in all subjects, at the
same time of the day.
Statistical analysis
All results were analyzed using the software package SPSS
for Windows Standard Version 13, 2004. Differences
between groups for variables at ordinal level were ana-
lyzed with a Mann-Whitney rank sum test. Differences in
age were analyzed with t-test. All ordinal correlation anal-
yses were performed with Kendall tau-b; otherwise a Pear-
son correlation coefficient was used. Reproducibility of
the VAS scales was quantified with the intraclass correla-
tion coefficient (ICC), based on one-way analysis of vari-
ance for repeated measurements [17]. The differences
between mean scores of the two measurements with their
95% confidence interval were calculated.
A Receiver Operating Characteristic (ROC) curve analysis
was used to determine the accuracy of the Visual Analogue
Scales.
Results were considered statistically significant when p <
.05.
Results
Sample characteristics
Demographic and clinical data of the sample are dis-
played in Table 1. Patient group and controls did not dif-
fer in age and gender distribution, but showed a
significant difference in fatigue scores.
Reliability
Of the three visual analogue scales VAS_1 showed the
smallest difference in raw scores in repeated assessment
after three days (Figures 2, 3, 4). The intraclass correlation
coefficient confirmed this observation (Table 2). Consid-
ering the total MS sample, the ICC was moderate for all
scales, with values ranging between 0.68 and 0.69. In the
subjects with better cognitive performance (RAO = 4), the
ICC values were similar in all scales. In subjects with a
RAO score of 3, the reproducibility of VAS_2 seemed
reduced, whereas the other scales showed similar ICC's.
Analysis of covariance did not reveal cognition as a covari-
Table 1: Demographic and clinical data of the sample
Subjects with MS n = 62 Healthy controls n = 24 p value
Age (mean, SD) 52 ± 10.5 52 ± 14.0 0.59°
Gender (F/M) 29/33 (47/53%) 13/11 (54/46%) 0.54*
EDSS (Me, IQR) 6.5 (3–8.5) -
Type MS (PP/RR/SP/NA) 14/16/20/12 -
VAS_1 (Me, IQR) 63 (39–76) 23 (5–60) <0.0001*
VAS_2 (Me, IQR) 43 (18–73) 3 (0–20) <0.0001*
VAS_3 (Me, IQR) 60 (35–79) 18 (3–51) <0.0001*
Fatigue Severity Scale (Me, IQR) 48 (34–56) 23 (15–32) <0.0001*
Modified Fatigue Impact Scale (Me, IQR) 43 (57–29) 24 (9–31) <0.0001*
Guy's NDS, subscale fatigue (Me, IQR) 3 (1–3) 0 (0–3) 0.01*
PP: primary progressive, RR: relapsing remitting, SP: secondary progressive, NA: data not available
Me: median, IRQ: interquartile range
° t-test * Mann-Whitney U testBMC Neurology 2006, 6:27 http://www.biomedcentral.com/1471-2377/6/27
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ate however. For all visual analogue scales no significant
differences in raw scores between groups (RAO = 4 versus
RAO = 3) existed.
Validity
VAS_1 correlated low to moderately with all fatigue scales
(values ranged from 0.28 to 0.48), whereas the correlation
coefficients of VAS_2 and VAS_3 with the other scales did
not reach higher levels than 0.37, indicating a weak asso-
ciation (Table 3). Considering the subscales of the Modi-
fied Fatigue Impact Scale (MFIS), mainly the physical
subscale accounted for the association with the VAS
scales. However, no significant relationships were found
between VAS scores and physical performance, assessed
with EDSS and the self-care domain of the Functional
Independence Measure. Besides, neither of the VAS scores
correlated with Zung depression scale or Rao's cognitive
battery. Fifty-two percent of the subjects scored more than
the mean depression score for depressed psychiatric out-
patients (score 51) studied by Zung (1965) [16]. How-
ever, no significant differences in VAS scores existed
between the non-depressed and depressed group.
Accuracy
The distribution of VAS scores in healthy controls and per-
sons with MS are displayed in Figure 5. All three scales
were able to discriminate between both groups (p <
0.0001); VAS_2 was the strongest tool to classify healthy
controls and subjects with MS (see also Additional file 1:
Discrimination between healthy controls and subjects
with MS: area under the ROC curve).
The subjects with a high level of fatigue were classified in
the fatigued group, using the cut-off value 36 of the
Fatigue Severity Scale (FSS) described in Flachenecker et
al. (2002). The accuracy of the VAS to correctly classify
subjects who are highly fatigued, was considered in an
ROC analysis. This analysis revealed that VAS_1 was most
appropriate for this purpose, with an area under the curve
of .78, whereas this value was .68 for VAS_2 and .71 for
VAS_3. A cut-off value on the VAS_1 of 59 displayed 76%
sensitivity and 72% specificity to discriminate between
fatigued and non-fatigued persons with MS (see Addi-
tional file 2: Discrimination between fatigued and non-
fatigued subjects with MS: cut-off values). When using the
critical value of the Modified Fatigue Impact Scale score to
discriminate between persons with high impact of fatigue
on their daily life (MFIS > 39) [18] and those with less
influence of fatigue, the VAS_1 remained the strongest
tool, with 81% sensitivity and 77% specificity at a cut-off
value of 59 (see Additional file 3: Discrimination between
high and low fatigue impact in subjects with MS: cut-off
values).
Difference in VAS_3 scores between first and second assess- ment Figure 4
Difference in VAS_3 scores between first and second assess-
ment.
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Difference in VAS_1 scores between first and second assess- ment Figure 2
Difference in VAS_1 scores between first and second assess-
ment.
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Difference in VAS_2 scores between first and second assess- ment Figure 3
Difference in VAS_2 scores between first and second assess-
ment.
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Figures 6 and 7 show the distribution of the scores of all
visual analogue scales. In contrast to VAS_2 and VAS_3,
VAS_1 was able to discriminate between fatigue (impact)
groups without substantial overlap of the interquartile
range. However, based on rank scores, differences
between groups were statistically significant in all three
VAS scales (Mann Whitney U test, p < 0.0001).
Discussion
This study aimed at finding a screening tool to assess rap-
idly the impact of fatigue on the daily life of subjects with
multiple sclerosis. Three visual analogue scales have been
developed and evaluated. The VAS that reflects all aspects
of daily life (VAS_1) had the highest reproducibility and
ability to detect people with high levels of fatigue
(impact).
The reproducibility of all scales was moderate (0.68–
0.69). Every millimeter of the scale can be considered as
one unit of the score, therefore visual analogue scales are
sensitive to a large variability. However, the difference in
raw VAS_1 scores between the two points of measurement
did not exceed 20% in most cases.
The correlations of VAS with other fatigue scales were low
to moderate, which implies different dimensions of
fatigue being assessed by various fatigue scales. Similar
results were reported in other studies [3,8,18,19]. The
weak correlation of the cognitive and psychosocial sub-
scales of MFIS with all three VAS scales suggests that the
visual analogue scales used in this study reflect the influ-
ence of fatigue on physical performance rather than on
cognitive and psychosocial abilities. One possible expla-
nation is that one does not always acknowledge the influ-
ence of fatigue on cognitive or psychosocial performance
and therefore these aspects are not reflected in the VAS
scores.
Of the three visual analogue scales, VAS_2 was most use-
ful in discriminating between healthy controls and per-
sons with MS. VAS_2 reflects the influence of fatigue on
personal care, which is apparently lower in controls. Every
human being experiences fatigue once in a while, but it
becomes pathological when it interferes with daily life
and certainly with self care. This idea is also generally
stated in the definition of the MS Council that describes
fatigue as the perception of "a subjective lack of physical
and/or mental energy...to interfere with usual and desired
activities" (p.2) [7].
Discrimination between high and low fatigue (impact)
within the MS group was most accurate in VAS_1, partic-
ularly when MFIS was used to classify subjects. This is
expected, of course, for the VAS_1 is a tool to assess the
impact of fatigue, which can be different from the severity
of fatigue quantified by the FSS. That is, individuals with
a similar level of fatigue severity do not necessarily experi-
ence similar fatigue impact. Therefore both features
should be assessed separately in order to plan interven-
tion strategies. The VAS in this study is developed to detect
persons with MS with high fatigue impact and, for exam-
ple, can be used as inclusion criterion for research pur-
poses. Especially when multiple data are collected (which
may provoke fatigue), the proposed VAS has the advan-
tage to provide a rapid impression of the level of fatigue
impact. In clinical practice however, a more elaborate
Table 3: Correlations with fatigue scales, Kendall's tau-b
VAS_1 VAS_2 VAS_3
Fatigue Severity Scale 0,45** 0,27** 0,37**
Modified Fatigue Impact Scale 
(MFIS)
0,41** 0,23** 0,32**
MFIS_physical subscale 0,48** 0,29** 0,36**
MFIS_cognitive subscale 0,28** 0,17 0,23**
MFIS_psychosocial subscale 0,39** 0,19* 0,26**
Guy's Neurological Disability Scale, 
fatigue subscale
0,43** 0,27** 0,37**
* p < 0.05, ** p < 0.01
Table 2: Reproducibility of the VAS scales: intraclass correlation with 95% confidence interval
Total MS sample (n = 62) Rao = 4 (n = 38) Rao = 3 (n = 24)
VAS_1 .69 (.53–.81) .72 (.52–.85) .67 (.31–.86)
VAS_2 .68 (.51–.80) .74 (.54–.85) .52 (.01–.79)
VAS_3 .69 (.53–.80) .65 (.42–.80) .74 (.42–.89)
Rao: Rao's cognitive batteryBMC Neurology 2006, 6:27 http://www.biomedcentral.com/1471-2377/6/27
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assessment of fatigue and the impact on daily life should
be performed in order to provide a tailor-made interven-
tion.
Although VAS_1 was the strongest scale to discriminate
between fatigued and non-fatigued subjects, the differ-
ence with the other visual analogue scales was moderate.
Additional research with these scales in other MS and con-
trol samples is needed to confirm our results.
A major concern in using self-report instruments is the
applicability in people with cognitive disabilities. We
selected individuals without major cognitive problems.
When the subjects without cognitive problems and those
with minor difficulties were analyzed separately, we
found similar reproducibility rates of the visual analogue
scales. Moreover, VAS did not correlate with cognitive per-
formance in this sample.
Despite the high incidence of depression in our sample,
VAS scores did not correlate with Zung's depression scale,
whereas MFIS showed low correlation (0.3). Depression is
often related to fatigue [20-27], but the causality of this
relationship is not clear. In general, depressed individuals
show higher fatigue levels; having disabling fatigue on its
turn may culminate in depression. In our sample, no
higher VAS-scores were found in the depressed group,
Scores of the VAS scales in subjects with low versus high  impact of fatigue (based on MFIS) Figure 7
Scores of the VAS scales in subjects with low versus 
high impact of fatigue (based on MFIS). Boxes repre-
sent 25–75% of the cases; whiskers are minimum and maxi-
mum values, lines: median values, °: outliers. Differences 
between groups are statistically significant (Mann Whitney U 
test, p < 0.0001).
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Distribution of VAS scores in healthy controls and persons  with MS Figure 5
Distribution of VAS scores in healthy controls and 
persons with MS. Boxes represent 25–75% of the cases; 
whiskers are minimum and maximum values, lines: median 
values, °: outliers, *: extreme values. Differences between 
groups are statistically significant (Mann Whitney U test, p < 
0.0001).
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Scores of the VAS scales in subjects with low versus high  fatigue (based on FSS) Figure 6
Scores of the VAS scales in subjects with low versus 
high fatigue (based on FSS). Boxes represent 25–75% of 
the cases; whiskers are minimum and maximum values, lines: 
median values, °: outliers. Differences between groups are 
statistically significant (Mann Whitney U test, p < 0.0001).
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however. These results support the construct validity of
the VAS, i.e. assessing the impact of fatigue and not of
depression.
A limitation of this study is the use of other self-report
instruments (MFIS and FSS) to split the sample in a non-
fatigued and a fatigued group. However, it is not straight-
forward to assess the symptom of fatigue otherwise. Sev-
eral methods have been proposed to objectively measure
fatigue, but these did not – or at best weakly – correlate
with perception of the symptom ([28-32]. Fatigue proba-
bly consists of multiple dimensions (e.g. motor versus
cognitive fatigue), that should be assessed by different
techniques.
The sample in our study showed a large variability in
EDSS scores (ranging from 3 to 8.5), and thus represented
the physical performance of the MS population to a great
extent. However, subjects in the lower boundaries of the
EDSS (0–2.5) were not included due to site bias (only per-
sons attending the rehabilitation centre entered the
study). The results of this study can therefore not be gen-
eralized to the whole MS population.
Conclusion
The Visual Analogue Scale for assessing the impact of
fatigue on daily life (VAS_1) is a moderately reliable,
though valid and useful tool to screen rapidly for fatigue
impact in multiple sclerosis. A cut-off value of 59 satisfac-
torily classifies individuals having severe fatigue with a
high impact on daily life. In clinical practice, a more com-
prehensive assessment of fatigue and the impact on daily
life is recommended.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
DK conceived of the study, participated in the design,
coordination and statistical analysis and drafted the man-
uscript. GN participated in the design and statistical anal-
ysis. MBD and MD participated in the design of the study
and interpretation of data. EK participated in the design,
coordination and statistical analysis. All authors critically
appraised and approved the final manuscript.
Additional material
Acknowledgements
Daphne Kos was supported by a PhD grant from the organization Weten-
schappelijk Onderzoek in Multiple Sclerose (WOMS) Belgium. We would 
like to thank Linsey Geentjens and Kristien Vuylsteke for selecting and test-
ing the controls.
References
1. Krupp LB: Fatigue Philadelphia, Elsevier Science; 2003. 
2. Pompeii LA, Moon SD, McCrory DC: Measures of physical and
cognitive function and work status among individuals with
multiple sclerosis: a review of the literature.  J Occup Rehabil
2005, 15:69-84.
3. Kos D, Kerckhofs E, Ketelaer P, Duportail M, Nagels G, D'Hooghe
MB, Nuyens G: Self-report assessment of fatigue in multiple
sclerosis: a critical evaluation.  Occupational Therapy in Health Care
2003, 17:45-62.
4. Guyatt GH, Townsend M, Berman LB, Keller JL: A comparison of
Likert and visual analogue scales for measuring change in
function.  J Chronic Dis 1987, 40:1129-1133.
5. Lee KA, Hicks G, Nino-Murcia G: Validity and reliability of a
scale to assess fatigue.  Psychiatry Res 1991, 36:291-298.
6. Rao S: A manual for the brief, repeatable battery of neuropsychological
tests in multiple sclerosis New York, National Multiple Sclerosis Society;
1990. 
7. Multiple Sclerosis Council for Clinical Practice Guidelines: Fatigue and
multiple sclerosis: evidence-based management strategies for fatigue in mul-
tiple sclerosis Washington (DC), Paralyzed Veterans of America;
1998:1-33. 
8. Kos D, Kerckhofs E, Nagels G, D'Hooghe BD, Duquet W, Duportail
M, Ketelaer P: Assessing fatigue in multiple sclerosis: Dutch
modified fatigue impact scale.  Acta Neurol Belg 2003,
103:185-191.
9. Kos D, Kerckhofs E, Carrea I, Verzo R, Ramos M, Jansa J: Evaluation
of the Modified Fatigue Impact Scale in four different Euro-
pean countries.  Mult Scler 2005, 11:76-80.
10. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD: The fatigue
severity scale. Application to patients with multiple sclerosis
and systemic lupus erythematosus.  Arch Neurol 1989,
46:1121-1123.
Additional file 1
Discrimination between healthy controls and subjects with MS. Receiver 
Operating Characteristic (ROC) curve analysis of the three VAS scales: 
area under the curve.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2377-6-27-S1.xls]
Additional file 2
Discrimination between fatigued and non-fatigued subjects with MS. 
Receiver Operating Characteristic (ROC) curve analysis of the three VAS 
scales: cut-off values.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2377-6-27-S2.xls]
Additional file 3
Discrimination between high and low fatigue impact in subjects with MS. 
Receiver Operating Characteristic (ROC) curve analysis of the three VAS 
scales: cut-off values.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2377-6-27-S3.xls]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Neurology 2006, 6:27 http://www.biomedcentral.com/1471-2377/6/27
Page 8 of 8
(page number not for citation purposes)
11. Sharrack B, Hughes RA: The Guy's Neurological Disability Scale
(GNDS): a new disability measure for multiple sclerosis.  Mult
Scler 1999, 5:223-233.
12. Nuyens G, Van Asch P, Kerckhofs E, Vleugels L, Duportail M, Ketelaer
P: The UK neurological disability scale: reliability and rela-
tion with the narcoms performance scale.  Int J MS Care 2002,
4:5.
13. Kurtzke JF: Rating neurologic impairment in multiple sclero-
sis: an expanded disability status scale (EDSS).  Neurology 1983,
33:1444-1452.
14. Keith RA, Granger CV, Hamilton BB, Sherwin SS: The functional
independence measure: a new tool for rehabilitation.  I n
Advances in clinical rehabilitation, Vol. 1. Edited by: Eisenberg MB and
Grzesiak RC. New York, Springer-Verlag; 1987:6-18. 
15. Rao SM, Leo GJ, Bernardin L, Unverzagt F: Cognitive dysfunction
in multiple sclerosis. I. Frequency, patterns, and prediction.
Neurology 1991, 41:685-691.
16. Zung WW: A self-rating depression scale.  Arch Gen Psychiatry
1965, 12:63-70.
17. Rankin G, Stokes M: Reliability of assessment tools in rehabili-
tation: an illustration of appropriate statistical analyses.  Clin
Rehabil 1998, 12:187-199.
18. Flachenecker P, Kumpfel T, Kallmann B, Gottschalk M, Grauer O,
Rieckmann P, Trenkwalder C, Toyka KV: Fatigue in multiple scle-
rosis: a comparison of different rating scales and correlation
to clinical parameters.  Mult Scler 2002, 8:523-526.
19. Chipchase SY, Lincoln NB, Radford KA: Measuring fatigue in peo-
ple with multiple sclerosis.  Disabil Rehabil 2003, 25:778-784.
20. Bakshi R, Shaikh ZA, Miletich RS, Czarnecki D, Dmochowski J, Hen-
schel K, Janardhan V, Dubey N, Kinkel PR: Fatigue in multiple scle-
rosis and its relationship to depression and neurologic
disability.  Mult Scler 2000, 6:181-185.
21. Lobentanz IS, Asenbaum S, Vass K, Sauter C, Klosch G, Kollegger H,
Kristoferitsch W, Zeitlhofer J: Factors influencing quality of life
in multiple sclerosis patients: disability, depressive mood,
fatigue and sleep quality.  Acta Neurol Scand 2004, 110:6-13.
22. Kroencke DC, Lynch SG, Denney DR: Fatigue in multiple sclero-
sis: relationship to depression, disability, and disease pattern.
Mult Scler 2000, 6:131-136.
23. Randolph JJ, Arnett PA, Higginson CI, Voss WD: Neurovegetative
Symptoms in Multiple Sclerosis: Relationship to Depressed
Mood, Fatigue, and Physical Disability.  Arch Clin Neuropsychol
2000, 15:387-398.
24. Voss WD, Arnett PA, Higginson CI, Randolph JJ, Campos MD, Dyck
DG:  Contributing factors to depressed mood in multiple
sclerosis.  Arch Clin Neuropsychol 2002, 17:103-115.
25. Chwastiak LA, Gibbons LE, Ehde DM, Sullivan M, Bowen JD, Bombar-
dier CH, Kraft GH: Fatigue and psychiatric illness in a large
community sample of persons with multiple sclerosis.  J Psy-
chosom Res 2005, 59:291-298.
26. Pittion-Vouyovitch S, Debouverie M, Guillemin F, Vandenberghe N,
Anxionnat R, Vespignani H: Fatigue in multiple sclerosis is
related to disability, depression and quality of life.  J Neurol Sci
2006, 243:39-45.
27. Schreurs KMG, de Ridder DTD, Bensing JM: Fatigue in multiple
sclerosis - Reciprocal relationships with physical disabilities
and depression.  J Psychosom Res 2002, 53:775-781.
28. Krupp LB, Elkins LE: Fatigue and declines in cognitive function-
ing in multiple sclerosis.  Neurology 2000, 55:934-939.
29. Schwid SR, Thornton CA, Pandya S, Manzur KL, Sanjak M, Petrie MD,
McDermott MP, Goodman AD: Quantitative assessment of
motor fatigue and strength in MS.  Neurology 1999, 53:743-750.
30. Schwid SR, Tyler CM, Scheid EA, Weinstein A, Goodman AD,
McDermott MP: Cognitive fatigue during a test requiring sus-
tained attention: a pilot study.  Mult Scler 2003, 9:503-508.
31. Kos D, Kerckhofs E, Nagels G, Geentjens L: Cognitive fatigue in
multiple sclerosis: comment on Schwid SR, Tyler CM, Scheid
EA, Weinstein A, Goodman AD and McDermott MR.  Mult
Scler 2004, 10:337.
32. Surakka J, Romberg A, Ruutiainen J, Virtanen A, Aunola S, Maentaka
K: Assessment of muscle strength and motor fatigue with a
knee dynamometer in subjects with multiple sclerosis: a new
fatigue index.  Clin Rehabil 2004, 18:652-659.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2377/6/27/prepub